D3Ertd254e Inhibitors
D3Ertd254e, predicted to exhibit DNA-binding transcription activator activity specific to RNA polymerase II, plays a key role in the regulation of transcription processes. While its functions are not extensively characterized, potential inhibitors targeting this protein can be explored to gain insights into its regulatory mechanisms. Actinomycin D, an established RNA polymerase II inhibitor, directly interferes with transcription by binding to the polymerase complex, hindering RNA chain elongation. Similarly, α-Amanitin, known for its potent inhibition of RNA polymerase II, obstructs mRNA synthesis by strongly binding to the polymerase. Triptolide, another RNA polymerase II inhibitor, suppresses transcriptional activity, impacting D3Ertd254e's DNA-binding transcription activator function.
Histone acetylation is a crucial aspect of transcription regulation. C646, a histone acetyltransferase inhibitor, targets PCAF, disrupting histone acetylation and indirectly influencing D3Ertd254e. Flavopiridol, a CDK inhibitor, affects the phosphorylation process associated with RNA polymerase II, impacting D3Ertd254e's regulatory role. DRB, functioning as both a kinase and RNA polymerase II inhibitor, disrupts the phosphorylation process linked to RNA polymerase II, influencing D3Ertd254e's function. CX-5461, primarily a RNA polymerase I inhibitor, indirectly influences RNA polymerase II and D3Ertd254e. Flavopiridol (Hydrochloride) impacts CDK9, altering the phosphorylation process associated with RNA polymerase II. AMG 900, an aurora kinase inhibitor, influences cell cycle progression and mitosis, indirectly impacting D3Ertd254e's transcriptional regulation. (+/-)-JQ1, a BET bromodomain inhibitor, disrupts the interaction between BRD4 and acetylated histones, indirectly affecting D3Ertd254e's DNA-binding transcription activator activity. The exploration of these inhibitors provides a foundation for understanding D3Ertd254e's regulatory mechanisms and opens avenues for further research into its functional significance in transcriptional processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D, a potent RNA polymerase inhibitor, directly targets RNA polymerase II. By binding to the transcription complex, Actinomycin D hinders the elongation of RNA chains, thus indirectly impeding D3Ertd254e's DNA-binding transcription activator activity and its regulatory role in transcription by RNA polymerase II. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
α-Amanitin, an RNA polymerase II inhibitor, directly targets RNA polymerase II. Through its strong binding to the polymerase, α-Amanitin obstructs mRNA synthesis, indirectly inhibiting D3Ertd254e's DNA-binding transcription activator activity and its involvement in the regulation of transcription by RNA polymerase II. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Triptolide, an RNA polymerase II inhibitor, directly targets RNA polymerase II. Its suppression of transcriptional activity indirectly influences D3Ertd254e's DNA-binding transcription activator activity, impacting its role in the regulation of transcription by RNA polymerase II. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
C646, a histone acetyltransferase (HAT) inhibitor, directly targets p300/CBP-associated factor (PCAF). By inhibiting PCAF, C646 disrupts histone acetylation, indirectly influencing D3Ertd254e's DNA-binding transcription activator activity and its participation in the regulation of transcription by RNA polymerase II. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
Flavopiridol, a CDK inhibitor, directly targets multiple cyclin-dependent kinases, including CDK9. Its inhibition of CDK9 affects the phosphorylation process associated with RNA polymerase II, indirectly influencing D3Ertd254e's DNA-binding transcription activator activity and its role in the regulation of transcription by RNA polymerase II. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
DRB, functioning as both a kinase and RNA polymerase II inhibitor, directly targets CDK9. By inhibiting CDK9, DRB disrupts the phosphorylation process linked to RNA polymerase II, indirectly influencing D3Ertd254e's DNA-binding transcription activator activity and its regulatory function in transcription by RNA polymerase II. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $245.00 | ||
CX-5461, a RNA polymerase I inhibitor, directly targets RNA polymerase I. While primarily focused on RNA polymerase I, CX-5461 indirectly influences RNA polymerase II, affecting D3Ertd254e's DNA-binding transcription activator activity and its regulatory role in transcription by RNA polymerase II. | ||||||
Flavopiridol Hydrochloride | 131740-09-5 | sc-207687 | 10 mg | $317.00 | ||
Flavopiridol (Hydrochloride), a CDK inhibitor, directly targets multiple cyclin-dependent kinases, including CDK9. Its impact on CDK9 alters the phosphorylation process linked to RNA polymerase II, indirectly influencing D3Ertd254e's DNA-binding transcription activator activity and its regulatory role in transcription by RNA polymerase II. | ||||||
(±)-JQ1 | 1268524-69-1 | sc-472932 sc-472932A | 5 mg 25 mg | $231.00 $863.00 | 1 | |
(+/-)-JQ1, a BET bromodomain inhibitor, directly targets BRD4. Its inhibition of BRD4 disrupts the interaction between BRD4 and acetylated histones, indirectly influencing D3Ertd254e's DNA-binding transcription activator activity and its role in the regulation of transcription by RNA polymerase II. | ||||||